Market Research Logo

Psoriatic Arthritis - Pipeline Review, H2 2015

Psoriatic Arthritis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Psoriatic Arthritis - Pipeline Review, H2 2015’, provides an overview of the Psoriatic Arthritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Psoriatic Arthritis Overview
Therapeutics Development
Pipeline Products for Psoriatic Arthritis - Overview
Pipeline Products for Psoriatic Arthritis - Comparative Analysis
Psoriatic Arthritis - Therapeutics under Development by Companies
Psoriatic Arthritis - Therapeutics under Investigation by Universities/Institutes
Psoriatic Arthritis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Psoriatic Arthritis - Products under Development by Companies
Psoriatic Arthritis - Products under Investigation by Universities/Institutes
Psoriatic Arthritis - Companies Involved in Therapeutics Development
AbbVie Inc.
AbGenomics International, Inc.
Alder Biopharmaceuticals Inc.
Amgen Inc.
AstraZeneca Plc
Avesthagen Limited
Berg LLC
BIOCAD
Biocon Limited
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celltrion, Inc.
Coherus BioSciences, Inc.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Forward Pharma A/S
Genor BioPharma Co., Ltd.
Hetero Drugs Limited
Inbiopro Solutions Pvt. Ltd.
Innovent Biologics, Inc.
Johnson & Johnson
Kineta, Inc.
Mabion SA
Mabtech Limited
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Novartis AG
Novo Nordisk A/S
Oncobiologics, Inc.
Panacea Biotec Limited
Pfizer Inc.
Sandoz International GmbH
Swedish Orphan Biovitrum AB
Therapeutic Proteins International, LLC
UCB S.A.
Vitae Pharmaceuticals, Inc.
Xbrane Bioscience AB
Psoriatic Arthritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
AbGn-168H - Drug Profile
ABT-122 - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
anakinra (recombinant) - Drug Profile
apremilast - Drug Profile
BI-655066 - Drug Profile
bimekizumab - Drug Profile
brodalumab - Drug Profile
certolizumab pegol biosimilar - Drug Profile
clazakizumab - Drug Profile
COVA-322 - Drug Profile
dalazatide - Drug Profile
dimethyl fumarate - Drug Profile
DNX-114 - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
golimumab - Drug Profile
golimumab biosimilar - Drug Profile
golimumab biosimilar - Drug Profile
golimumab biosimilar - Drug Profile
guselkumab - Drug Profile
IBI-303 - Drug Profile
IBPM-004AM - Drug Profile
IBPM-005IX - Drug Profile
infliximab biobetter - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
INV-17 - Drug Profile
itolizumab - Drug Profile
ixekizumab - Drug Profile
liraglutide (recombinant) - Drug Profile
Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - Drug Profile
secukinumab - Drug Profile
tofacitinib - Drug Profile
ubidecarenone - Drug Profile
ustekinumab biosimilar - Drug Profile
ustekinumab biosimilar - Drug Profile
VTP-43742 - Drug Profile
Psoriatic Arthritis - Recent Pipeline Updates
Psoriatic Arthritis - Dormant Projects
Psoriatic Arthritis - Discontinued Products
Psoriatic Arthritis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Psoriatic Arthritis, H2 2015
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Psoriatic Arthritis - Pipeline by AbbVie Inc., H2 2015
Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H2 2015
Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H2 2015
Psoriatic Arthritis - Pipeline by Amgen Inc., H2 2015
Psoriatic Arthritis - Pipeline by AstraZeneca Plc, H2 2015
Psoriatic Arthritis - Pipeline by Avesthagen Limited, H2 2015
Psoriatic Arthritis - Pipeline by Berg LLC, H2 2015
Psoriatic Arthritis - Pipeline by BIOCAD, H2 2015
Psoriatic Arthritis - Pipeline by Biocon Limited, H2 2015
Psoriatic Arthritis - Pipeline by Bionovis SA, H2 2015
Psoriatic Arthritis - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Psoriatic Arthritis - Pipeline by Celgene Corporation, H2 2015
Psoriatic Arthritis - Pipeline by Celltrion, Inc., H2 2015
Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H2 2015
Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H2 2015
Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H2 2015
Psoriatic Arthritis - Pipeline by Genor BioPharma Co., Ltd., H2 2015
Psoriatic Arthritis - Pipeline by Hetero Drugs Limited, H2 2015
Psoriatic Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H2 2015
Psoriatic Arthritis - Pipeline by Johnson & Johnson, H2 2015
Psoriatic Arthritis - Pipeline by Kineta, Inc., H2 2015
Psoriatic Arthritis - Pipeline by Mabion SA, H2 2015
Psoriatic Arthritis - Pipeline by Mabtech Limited, H2 2015
Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2015
Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc., H2 2015
Psoriatic Arthritis - Pipeline by Novartis AG, H2 2015
Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H2 2015
Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H2 2015
Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H2 2015
Psoriatic Arthritis - Pipeline by Pfizer Inc., H2 2015
Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H2 2015
Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H2 2015
Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H2 2015
Psoriatic Arthritis - Pipeline by UCB S.A., H2 2015
Psoriatic Arthritis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015
Psoriatic Arthritis - Pipeline by Xbrane Bioscience AB, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H2 2015
Psoriatic Arthritis - Dormant Projects, H2 2015
Psoriatic Arthritis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Psoriatic Arthritis, H2 2015
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report